President and Chief Executive Officer · Mersana Therapeutics, Inc. (MRSN)

Martin Huber

A named executive officer of Mersana Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,613,754

Salary $632,500Stock awards $133,635

FY2023: $2,601,249

1st of 5 named executive officers at Mersana Therapeutics by FY2024 total.

5 named officers on file for Mersana Therapeutics, FY2024

Martin Huber’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • MRSN’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mersana Therapeutics’s whole pay program stands against its peers

  • Mersana Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MRSN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Martin Huber’s full pay file as a PDF — free

More than this page: up to 10 years of Martin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Martin Huber compensation by year

Mersana Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Mersana Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$194,311$632,500
Bonus$0$0
Stock awards$880,440$133,635
Option awards$1,133,300$518,044
Non-equity incentive$110,466$322,575
Pension and deferred compensation$0$0
All other$282,733$7,000
Total$2,601,249$1,613,754

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mersana Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001104659-25-040448, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mersana Therapeutics, Inc. filed document, accession 0001104659-25-040448. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

$2.6M
$1.6M
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU500,250$715,358—
RSU44,250$63,278—
Option687,500—$1.32
Option161,789—$3.02

Per the Outstanding Equity Awards at Fiscal Year-End table in Mersana Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

22 Form 4 lines since the FY2024 proxy (filed April 29, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-06Disposition to the issuer derivative—99—0
2026-01-06Disposition to the issuer derivative—26,713—0
2026-01-06Disposition to the issuer derivative—1,328—0
2026-01-06Disposition to the issuer derivative—5,938—0
2026-01-06Disposition to the issuer derivative—27,878—0
2026-01-06Disposition to the issuer derivative—1,002—0
2026-01-06U—9,573—0
2026-01-06Disposition to the issuer derivative—734—0

The 8 most recent of 22 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Mersana Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Martin Huber · this pagePresident and Chief Executive Officer$1,613,754
Brian DeSchuytnerSenior Vice President, Chief Operating Officer and Chief Financial Officer$1,543,586
Mohan BalaSenior Vice President, Chief Development Officer$1,502,936
Timothy LowingerSenior Vice President, Chief Science and Technology Officer$1,400,535
Alejandra CarvajalSenior Vice President, Chief Legal Officer$1,359,885

Board service

Mersana Therapeutics board · FY2021–FY2024
Director compensation in US dollars, as Mersana Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2024—————
FY2022$44,000—$119,192—$163,192
FY2021$40,000—$250,047—$290,047

Each year as the company reported it in Mersana Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Mersana Therapeutics pays directors a $40,000 cash retainer and $105,996 in Options. As stated in Mersana Therapeutics's FY2024 proxy.

The full Mersana Therapeutics compensation record

free company brief

This page is one person within Mersana Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mersana Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mersana Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Martin Huber's compensation dossier · One-time report. No refunds.